Biological and engineering considerations for developing tumor-targeting metallic nanoparticle drug-delivery systems

Nanoparticulate Drug Delivery Systems

Volumn , Issue , 2007, Pages 141-158

  Paciotti, Giulio F ^a   Tamarkin, Lawrence ^a  

^a Cytlmmune Sciences Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954875422     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (108)

1. Papisov MI. Theoretical considerations of RES-avoiding liposomes: molecular mechanisms and chemistry of liposome interactions. Adv Drug Deliv Rev 1998; 32:119-138.
2. Moghimi SM, Patel HM. Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system-the concept of tissue specificity. Adv Drug Deliv Rev 1998; 32:45-60.
3. Woodle MC. Controlling liposome blood clearance by surface grafted polymers. Adv Drug Deliv Rev 1998; 32:139-152.
4. Nafayasu A, Uchiyama K, Kiwada H. The size of liposomes: a factor, which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv Drug Deliv Rev 1999; 40:75-87.
5. Maruyama K, Ishida O, Takizawa T, Moribe K. Possibility of active targeting to tumor tissues with liposomes. Adv Drug Deliv Rev 1999; 40:89-102.
6. Salata OV. Applications of nanoparticles in biology and medicine. J. Nanotechnol 2004; 2:3-8.
7. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J 2005; 19:311-330.
8. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001; 53:283-318.
9. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005; 5:161-171.
10. Müller RH, Mäder K, Gohla S. Solid-lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 2000; 50:161-177.
11. Jain R, Shah NH, Malick AW, Rhodes CT. Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches. Drug Dev Indust Pharm 1998; 24:703-727.
12. Rafferty DE, Elfaki MG, Montgomery PC. Preparation and characterization of a biodegradable microparticle antigen/cytokine delivery system. Vaccine 1996; 14:532-538.
13. Ogawa Y. Injectable microcapsules prepared with biodegradable poly(a-hydroxy) acids for prolonged release of drugs. J Biomater Sci Polym Ed 1997; 8:391-109.
14. Maruyama K, Takizawa T, Takahashi N, et al. Targeting efficiency of PEG-immunoli-posome-conjugated antibodies at PEG terminals. Adv Drug Deliv Rev 1998; 24:235-242.
15. Absolom D. Opsonins and dysopsonins: an overview. Methods Enzymol 1986; 132:281-318.
16. Patel HM. Serum opsins and liposomes: their interaction and opsonophagocytosis. Crit Rev Ther Drug Carrier Syst 1992; 9:39-90.
17. Serra MV, Mannu F, Mater A, Turrini F, Arese P. Enhanced IgG and complement-independent phagocytosis of sulfatide-enriched human erythrocytes by human monocytes. FEBS Lett 1992; 311:67-70.
18. Chonn A, Cullis PR, Devine DV. The role of surface charge in the activation of the classic and alternative pathways of complement activation by liposomes. J Immunol 1991; 146:4234-4241.
19. Moghimi SM, Patel HM. Altered tissue specific opsonic activities and opsonophagocytosis of liposomes in tumor bearing rats. Biochem Biophys Acta 1996; 1179:157-165.
20. Abra RM, Bosworth ME, Hunt CA. Liposome disposition in vivo: effect of pre-dosing with liposomes. Res Commun Chem Pathol Pharmacol 1980; 29:349-360.
21. Souhami RL, Patel HM, Ryman BE. The effect of reticuloendothelial blockade on the blood clearance and tissue distribution of liposomes. Biochem Biophys Acta 1981; 674:354-371.
22. Moghimi SM, Davis SS. Innovations in avoiding particle clearance from the blood by Kupffer cells: cause for reflection. Crit Rev Ther Drug Carrier Syst 1994; 11:31-59.
23. Bergqvist L, Sundberg R, Ryden S, Strand SE. The "critical colloid dose" in studies of reticuloendothelial function. J Nucl Med 1987; 28:1424-1429.
24. Bradfield JW. A new look at reticuloendothelial blockade. Br J Exp Pathol 1980; 61:617-623.
25. Baban DF, Seymour LW. Control of tumour vascular permeability. Adv Drug Deliv Rev 1998; 34:109-119.
26. Cleland JL. Protein delivery from biodegradable microspheres. In: Sanders, Hendren, eds. Protein Delivery: Physical Systems. New York: Plenum Press, 1997:1-43.
27. Illum L, Davis SS, Muller RH, Mak E, West P. The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer- poloxamine 908. Life Sci 1987; 40:367-374.
28. Redhead HM, Davis SS, Illum L. Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. J Control Release 2001; 70:353-363.
29. Moghimi SM. Modulation of lymphatic distribution of subcutaneously injected poloxamer 407-coated nanospheres: the effect of ethylene oxide chain configuration. FEBS Lett 2003; 241-244.
30. Paciotti GF, Myer L, Weinreich D, et al. Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv 2004; 11:169-183.
31. Chen LT, Weiss L. The role of the sinus wall in the passage of erythrocytes through the spleen. Blood 1973; 41:529-573.
32. Moghimi SM, Porter CJH, Muir IS, Illum L, Davis SS. Non-phagocytic uptake of intravenously injected microspheres in the rat spleen: influence of particle size and hydrophilic coating. Biochem Biophys Res Commun 1991; 177:861-866.
33. Senior J, Gregoriadis G. Is half-life of circulating small unilamellar liposomes determined by changes in their permeability. FEBS Lett 1982; 145:109-114.
34. Volakanis JE, Wirtz K. Interaction of C-reactive protein with artificial phosphatidylcholine bilayer. Nature (Lond) 1979; 281:115-157.
35. Devine DV, Bradley AJ. The complement system in liposome clearance: can complement deposition be inhibited? Adv Drug Deliv Rev 1998; 32:19-39.
36. Thurston G, McLean JW, Rizen M, et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest 1998; 101:1401-1413.
37. Campbell RB, Fukuruma D, Brown EB, Mazzola LM, Izumi Y, Jain RK. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartment. Can Res 2002; 61:6831-6836.
38. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
39. Daly ME, Markis A, Reed M, Lewis CE. Homeostatic regulators of tumor angiogenesis: a source of antiangiogenic agents for cancer treatment? J Natl Cancer Inst 2003; 95:1660-1673.
40. Heemskerk JW, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost 2002; 88:186-193.
41. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Natl Med 2000; 6:389-395.
42. Pinedo HM, Verheul HM, D'Amato RJ, Folkman J. Involvement of platelets in tumor angiogenesis? Lancet 1998; 352:1775-1777.
43. Chen J, Bierhaus A, Schiekofer S, et al. Tissue factor-a receptor involved in the control of cellular properties, including angiogenesis. Thromb Haemost 2001; 86:334-345.
44. Kakkar AK, Lemoine NR, Scully MF, Tebbutt S, Williamson RC. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 1995; 82:1101-1104.
45. Hamada K, Kuratsu J, Saitah Y, Takeshima H, Nishi T, Ushio Y. Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer 1996; 77:1877-1883.
46. Gasic GJ, Gasic TB, Stewart CC. Anti-metastatic effects associated with platelet reduction. PNAS (USA) 1968; 61:46-52.
47. Cramerer E, Qazi AA, Duong D, Cornelissen I, Advincula R, Coughlin SR. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 2004; 104:397-401.
48. Mantovani A, Sozzani S, Locati M, Allavena P, Sica. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononulcear phagocytes. Trends Immunol 2002; 23:549-555.
49. Elgert KD, Alleva DG, Mullins DW. Tumor induced immune dysfunction: the macrophage connection. J Leukoc Biol 1998; 64:2765-290.
50. Watson GA, Fu YX, Lopez DM. Splenic macrophages from tumor-bearing mice co-expressing MAC-1 and MAC-2 antigens exert immunoregulatory functions via two distinct pathways. J Leukoc Biol 1991; 49:126-138.
51. Watson GA, Lopez DM. Aberrant antigen presentation by macrophages from tumor-bearing mice is involved in the downregulation of their T-cell responses. J Immunol 1995; 155:124-134.
52. Burke B, Tang N, Corke KP, et al. Expression of HIF-1a by human macrophages: implications for the use of hypoxia-regulated cancer therapy. J Pathol 2002; 196:204-212.
53. Murdoch C, Giannoudis A, Lewis CE. Mechanism of regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004; 104:2224-2234.
54. Burke B, Giannoudis A, Corke KP, et al. Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia regulated gene therapy. Am J Pathol 2003; 163:1233-1243.
55. Koshikawa N, Iyozumi A, Gassmann M, Takenaga K. Constitutive upregulation of hypoxia-inducible factor-1 alpha mRNA occurring in highly metastatic carcinoma cells leads to vascular endothelial growth factor overexpression under hypoxic exposure. Oncogene 2003; 22:6717-6724.
56. Kuwai T, Tanaka KY, Tanaka S, et al. Expression of hypoxia-inducible factor-1 alpha is associated with tumor vascularization in human colorectal carcinoma. Int J Cancer 2003; 105:176-181.
57. Kohn S, Nagy JA, Dvorak HF, et al. Pathways of macromolecular tracer transport across venules and small veins: structural basis for the hyperpermeability of tumor blood vessels. Lab Invest 1992; 67:596-607.
58. Dvorak AM, Kohn S, Morgan ES, et al. The vesiculo-vacuolar organelle (VVO): a distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation. J Leukoc Biol 1996; 59:100-115.
59. Feng D, Nagy J, Hipp J, et al. Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. J Exp Med 1996; 183:1981-1986.
60. Hashizume H, Baluk P, Morikawa S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000; 156:1363-1380.
61. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003; 9:685-693.
62. Mukouyama YS, Shin D, Britsch S, Tabiguchi M, Anderson DJ. Sensory nerves determine the pattern of arterial differentiation and blood vessel branching in the skin. Cell 2002; 109:693-705.
63. Neufeld G, Cohen T, Shraga N, Lange T, Kessler O, Herzog Y. The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. Trends Cardiovasc Med 2002; 12:13-19.
64. Eichmann A, Le Noble F, Autiero M, Carmeliet P. Guidance of vascular and neural network formation. Curr Opin Neurobiol 2005; 15:108-115.
65. Nagy JA, Masse EM, Herzberg KT, et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 1995; 55:360-368.
66. Lichtenbeld HC, Yuan F, Michel CC, Jain RK. Perfusion of single tumor microvessels: application to vascular permeability measurement. Microcirculation 1996; 3:349-357.
67. Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM. Vascular permeability factor vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 1999; 237:97-132.
68. Chang YS, diTomaso E, McDonald DM, Jones R, Jain RK. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. PNAS 2000; 97:14608-14613.
69. Monsky WL, Carreira CM, Tsuzuki Y, Gohongi T, Fukumara Y, Jain RK. Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumors. Clin Cancer Res 2002; 8:1008-1013.
70. Tong RT, Yves Boucher Y, Sergey V, et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64:3731-3736.
71. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58-62.
72. Alexander HR, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 1998; 16:1479-1489.
73. Lejeune FJ. High dose recombinant tumour necrosis factor (rTNFa) administered by isolation perfusion for advanced tumors of the limbs: a model for biochemotherapy of cancer. Eur J Cancer 1995; 31:1009.
74. Lienard D, Lejeune F, Ewalenko I. In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion. World J Surg 1992; 16:234.
75. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72:3666.
76. Helson L, Green S, Carswell EA, Old LJ. Effect of tumor necrosis factor on cultured human melanoma cells. Nature 1975; 258:731.
77. Asami T, Iami M, Tanaka Y. In vivo anti-tumor mechanism of natural human tumor necrosis factor involving a T-cell mediated immunologic route. Jpn J Cancer Res 1989; 80:1161.
78. Nawroth PP, Stern DM. Modulation of endothelial cell homeostatic properties by tumor necrosis factor. J Exp Med 1986; 163:740.
79. Brett J, Gerlach H, Nawroth P, Steinberg S, Godman G, Stern D. Tumor necrosis factor/ cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins. J Exp Med 1989; 168:637.
80. Kristensen CA, Nozue M, Boucher Y, Jain RK. Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts. Br J Cancer 1996; 74:533.
81. Nedrebo T, Berg A, Reed RK. Effect of tumor necrosis factor-A, IL-1ß, and IL-6 on interstitial fluid pressure in rat skin. Heart Circ Physiol 1999; 46:H1857.
82. van der Veen AH, deWilt JHW, Eggermont AMM, van Tiel ST, Seynhaeve ALB, ten Hagen TLM. TNF-A augments intratumoral concentrations of doxorubicin in TNF-A based isolated limb perfusion in rat sarcoma models, and enhances anti-tumor effects. Br J Cancer 2000; 82:973-980.
83. Pluen A, Boucher Y, Ramanujan S, et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. PNAS 2001; 98:4628-1633.
84. Cristiano RJ, Roth JA. Epidermal growth-factor mediated DNA delivery into lung-cancer cells via the epidermal growth factor receptor. Cancer Gene Ther 1996; 3:4-10.
85. Gottschalk S, Cristiano RJ, Smith LC, Woo SLC. Folate-mediated receptor mediated DNA delivery into tumor cells-postsomal disruption results in enhanced gene-expression. Gene Ther 1994; 1:185-191.
86. Singh M. Transferrin as a targeting ligand for liposomes and anticancer drugs. Curr Pharm Des 1999; 5:443-451.
87. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002; 110:475-482.
88. Tuffin G, Waelti E, Huwyler J, Hammer C, Marti HP. Immunoliposomes targeting mesangial cells: a promising strategy for specific drug delivery to the kidney. J Am Soc Nephrol 2005; 16:3395-3305.
89. Sachdeva MS. Drug targeting systems for cancer chemotherapy. Expert Opin Invest Drug 1998; 7:1849-1864.
90. Marketing survey. Robert H. Smith School of Business, University of Maryland College Park, April 2004.
91. Faraday M. Experimental relations of gold (and other metals) to light. Philos Trans R Soc London 1857; 14:145.
92. Chandler J, Robinson N, Whiting K. Handling false signals in gold-based tests. IVD Technol 2001; 7:34.
93. Mirkin CA, Letsinger RL, Mucic RC, Storhoff JJ. A DNA based method for rationally assembling nanoparticles into macroscopic materials. Nature 1996; 382:607.
94. Berry CC, Curtis ASG. Functionalisation of magnetic nanoparticles for applications in biomedicine. J Phys Appl Phys 2003; 36:R198-R206.
95. Rubin P, Levitt SH. The response of disseminated reticulum cell sarcoma to the intravenous injection of colloidal radioactive gold. J Nucl Med 1964; 5:581.
96. Root SW, Andrews GA, Knieseley RM, Tyor MP. The distribution and radiation effects of intravenously administered colloidal Au 198 in man. Cancer 1954; 7:856.
97. Tang L, Liu L, Elwing HB. Complement activation and inflammation triggered by model biomaterial surfaces. J Biomed Mater Res 1998; 41:333-340.
98. Alexiou C, Arnold W, Klein RJ, et al. Locoregional cancer treatment with magnetic targeting. Can Res 2001; 60:6641-6648.
99. Lubbe AS, Alexiou C, Bergemann C. Clinical applications of magnetic drug targeting. J Surg Res 2001; 95:200-206.
100. Lubbe AS, Alexiou C, Reiss H, et al. Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubidin in 14 patients with advanced solid tumors. Cancer Res 1996; 56:4686-4693.
101. Hermanson GT. Bioconjugate Techniques. Academic Press, 1996:594-597.
102. Allport JR, Weissleder. In vivo imaging of gene and cell therapies. Exp Hematol 2001; 29:1237-1246.
103. Jain TK, Morales MA, Sahoo SK, Leslie-Pelecky DL, Labhasetwar. Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol Pharm 2005; 2:194-205.
104. Gilchrist RK, Medal R, Shorey WD, Hanselman RC, Parrot JC, Taylor CB. Selective inductive heating of lymph nodes. Ann Surg 1957; 146:596-606.
105. Jordan A, Wust P, Scholz R, et al. Cellular uptake of magnetic fluids particles and their effects on human adenocarcinoma cells exposed to AC magnetic fields in vitro. Int J Hyperthermia 1996; 12:705-722.
106. Neilsen OS, Horsman M, Overgaard J. A future for hyperthermia in cancer treatment? Eur J Cancer 2001; 37:1587-1589.
107. Babincova M, Sourivong P, Leszczynska D, Babinec P. Blood-specific whole-body electromagnetic hyperthermia. Med Hypotheses 2000; 55:459-460.
108. Hirsch LR, Stafford RJ, Bankson JA, et al. Nanoshell-mediated near infra-red thermal therapy of tumors under magnetic resonance guide. PNAS 2003; 100:13549-13554.